ion, we appreciate the opportunity to clarify our findings. Despite influencing factors, our data support SBRT as a promising and safe treatment option with advantages, such as reduced toxicity and retreatment feasibility. We acknowledge the complexity of evaluating adverse events but emphasize that our findings highlight SBRT’s potential for effective ovarian cancer lesion management. We hope this exchange enhances understanding of SBRT’s clinical role and fosters continued dialogue in this field
Macchia, G., Pezzulla, D., Ferrandina, M. G., Deodato, F., In Reply to Gurlek et al, <<INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS>>, 2025; 121 (5): 1401-1402. [doi:10.1016/j.ijrobp.2024.12.030] [https://hdl.handle.net/10807/326095]
In Reply to Gurlek et al
Macchia, Gabriella;Ferrandina, Maria Gabriella;Deodato, Francesco
2025
Abstract
ion, we appreciate the opportunity to clarify our findings. Despite influencing factors, our data support SBRT as a promising and safe treatment option with advantages, such as reduced toxicity and retreatment feasibility. We acknowledge the complexity of evaluating adverse events but emphasize that our findings highlight SBRT’s potential for effective ovarian cancer lesion management. We hope this exchange enhances understanding of SBRT’s clinical role and fosters continued dialogue in this field
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
